Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
14 janv. 2020 00h30 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...
Biofrontera reports preliminary unaudited sales revenue for the first six months of 2019
09 juil. 2019 12h05 HE
|
Biofrontera AG
Leverkusen, Germany, July 09, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical...
Biofrontera provides corporate update; conference call details for March 26, 2019
25 mars 2019 11h30 HE
|
Biofrontera AG
Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a...
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
20 mars 2019 10h50 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
Biofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz®
19 mars 2019 07h42 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to...
Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production
08 janv. 2019 02h02 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz® in the EU
17 sept. 2018 05h17 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on...
Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018
03 sept. 2018 05h35 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...